| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.5829 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.6071 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.6192 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.6899 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.6970 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7062 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7076 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7153 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7169 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7233 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7284 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7343 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7351 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7372 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7415 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7577 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7581 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7600 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7691 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7728 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7777 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7821 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7832 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.7914 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8036 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8055 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8073 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8098 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8120 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8125 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8248 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8292 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8320 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8380 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8422 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8425 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8449 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8460 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8523 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8535 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8542 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8635 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8649 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8687 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8709 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8710 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8748 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8790 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8805 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8843 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8848 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8906 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8923 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8975 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.8998 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9004 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9111 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9125 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9128 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9139 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9223 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9225 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9285 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9335 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9350 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9378 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9413 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9436 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9457 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9457 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9506 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9580 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9615 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9640 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9660 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9711 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9747 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9768 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9771 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9785 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9795 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9806 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9901 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9904 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9905 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9916 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9929 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9936 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9942 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9943 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9946 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9955 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 0.9994 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0000 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0071 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0080 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0134 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0167 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0203 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0218 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0224 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0291 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0358 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0416 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0430 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0461 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0509 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0562 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0594 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0594 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0618 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0628 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0632 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0688 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0698 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0712 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0718 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0773 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.0781 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1002 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1052 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1054 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1122 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1147 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1209 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1246 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1300 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1396 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1404 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1418 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1425 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1490 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1535 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1557 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1594 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1594 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1601 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1641 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1744 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.1811 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2025 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2075 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2105 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2137 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2190 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2197 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2211 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2377 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2480 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2739 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2772 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.2922 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3033 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3185 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3503 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3577 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3625 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3771 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.3942 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.4395 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.4422 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.4572 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.5835 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.5876 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.5993 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.6052 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.6225 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.6265 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.6537 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.6829 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7054 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7086 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7183 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7424 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7511 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.7742 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.8011 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.8158 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.8809 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.8938 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.9170 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 1.9253 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 2.0247 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 2.4423 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 2.4845 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 2.5026 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidate (20:0) | 2.6612 | scaled units | High-Dose | +23HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|